

this paper. However, if additional extensions of time are necessary to prevent abandonment of this application, then such extensions of time are hereby petitioned under 37 C.F.R. § 1.136(a), and any fees required therefor (including fees for net addition of claims) are hereby authorized to be charged to our Deposit Account No. 19-0036.

*Amendments*

*In the Claims:*

*Please replace pending claim 82 with the following claim 82.*

91 82. (Once amended) The pharmaceutical composition of claim 81, wherein the epitope consists of the amino acid sequence TTLFCASDAK (SEQ ID NO:32).

*Please replace pending claim 89 with the following claim 89.*

92 89. (Once amended) The diagnostic agent of claim 88, wherein the peptide consists of the amino acid sequence TTLFCASDAK (SEQ ID NO:32).

*Please replace pending claim 90 with the following claim 90.*

93 90. (Once amended) An isolated cytolytic T cell line which specifically recognizes a complex of an HLA-A3 molecule and a peptide epitope of about 11 amino acids having the amino acid sequence TTLFCASDAK (SEQ ID NO:32).

*Please replace pending claim 93 with the following claim 93.*

94

93. (Once amended) The isolated antigenic HLA-A3 binding peptide of claim 92 consisting of the amino acid sequence TTLFCASDAK (SEQ ID NO:32).

*Please replace pending claim 94 with the following claim 94.*

95

94. (Once amended) An isolated nucleic acid molecule consisting of a nucleotide sequence encoding the amino acid sequence TTLFCASDAK (SEQ ID NO:32).